Skip to content
Revelation News
Sign inSign up
Zipalertinib Combined with Chemotherapy Significantly Improves Progression-Free Survival in First-Line EGFR Lung CancerRDNE Stock project · Pexels
Health

Zipalertinib Combined with Chemotherapy Significantly Improves Progression-Free Survival in First-Line EGFR Lung Cancer

Source Summary

Zipalertinib added to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations receiving first-line treatment. The results were presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer.

Why it matters

This combination therapy demonstrates a significant clinical benefit for a specific subset of lung cancer patients with EGFR exon 20 insertion mutations, potentially offering an improved treatment option for this population.

Read the Source